File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Biodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice

TitleBiodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice
Authors
Issue Date2022
Citation
Biomaterials Science, 2022, v. 10, p. 984-996 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/313797
ISSN
2023 Impact Factor: 5.8
2023 SCImago Journal Rankings: 1.206
ISI Accession Number ID
AwardObesity is hallmarked by endoplasmic reticulum (ER) stress, chronic inflammation and metabolic dysfunctions. The control of obesity is the key to preventing the onset of non-alcoholic fatty liver disease, diabetes, cerebro-cardiovascular diseases and cancers. As a promising anti-obesity drug, plant-derived celastrol is challenged by poor water solubility and low oral bioavailability in clinical applications. The present study was designed to develop a biocompatible albumin-based nanoparticle carrier system for the controlled release of celastrol in diet-induced obese mice. Celastrol was loaded into bovine serum albumin (BSA) nanoparticles to yield celastrol-BSA-NPs by high pressure homogenization. Celastrol-BSA-NPs exhibited spherical morphology, narrow size distribution with a diameter of 125.6 ± 2.2 nm, satisfactory drug-loading efficiency at 13.88 ± 0.12% and a sustained-release profile over a period of 168 h. Compared with free celastrol, celastrol-BSA-NPs effectively improved cellular uptake, intestinal absorption and hepatic deposition. In animal experiments, celastrol-BSA-NPs outperformed free celastrol in lowering lipid accumulation, improving insulin sensitivity, and reducing inflammation in diet-induced obesity. Collectively, celastrol-BSA-NPs exhibited better bioavailability and in vivo efficacy in the treatment of diet-induced obesity. Importantly, such albumin-based nanoparticles may be a general biocompatible drug carrier system for the controlled release of hydrophobic compounds (e.g., celastrol) for the treatment of obesity and non-alcoholic fatty liver disease.

 

DC FieldValueLanguage
dc.contributor.authorFAN, N-
dc.contributor.authorZhao, J-
dc.contributor.authorZhao, W-
dc.contributor.authorSHEN, Y-
dc.contributor.authorSONG, Q-
dc.contributor.authorShum, HC-
dc.contributor.authorWang, Y-
dc.contributor.authorRong, J-
dc.date.accessioned2022-07-05T05:05:53Z-
dc.date.available2022-07-05T05:05:53Z-
dc.date.issued2022-
dc.identifier.citationBiomaterials Science, 2022, v. 10, p. 984-996-
dc.identifier.issn2047-4830-
dc.identifier.urihttp://hdl.handle.net/10722/313797-
dc.languageeng-
dc.relation.ispartofBiomaterials Science-
dc.titleBiodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice-
dc.typeArticle-
dc.identifier.emailZhao, J: zhaojia7@hku.hk-
dc.identifier.emailShum, HC: ashum@hku.hk-
dc.identifier.emailWang, Y: yuwanghk@hku.hk-
dc.identifier.emailRong, J: jrong@hku.hk-
dc.identifier.authorityShum, HC=rp01439-
dc.identifier.authorityWang, Y=rp00239-
dc.identifier.authorityRong, J=rp00515-
dc.identifier.doi10.1039/D1BM01637G-
dc.identifier.pmid35019905-
dc.identifier.scopuseid_2-s2.0-85124636402-
dc.identifier.hkuros333969-
dc.identifier.volume10-
dc.identifier.spage984-
dc.identifier.epage996-
dc.identifier.isiWOS:000741639800001-
dc.description.awardObesity is hallmarked by endoplasmic reticulum (ER) stress, chronic inflammation and metabolic dysfunctions. The control of obesity is the key to preventing the onset of non-alcoholic fatty liver disease, diabetes, cerebro-cardiovascular diseases and cancers. As a promising anti-obesity drug, plant-derived celastrol is challenged by poor water solubility and low oral bioavailability in clinical applications. The present study was designed to develop a biocompatible albumin-based nanoparticle carrier system for the controlled release of celastrol in diet-induced obese mice. Celastrol was loaded into bovine serum albumin (BSA) nanoparticles to yield celastrol-BSA-NPs by high pressure homogenization. Celastrol-BSA-NPs exhibited spherical morphology, narrow size distribution with a diameter of 125.6 ± 2.2 nm, satisfactory drug-loading efficiency at 13.88 ± 0.12% and a sustained-release profile over a period of 168 h. Compared with free celastrol, celastrol-BSA-NPs effectively improved cellular uptake, intestinal absorption and hepatic deposition. In animal experiments, celastrol-BSA-NPs outperformed free celastrol in lowering lipid accumulation, improving insulin sensitivity, and reducing inflammation in diet-induced obesity. Collectively, celastrol-BSA-NPs exhibited better bioavailability and in vivo efficacy in the treatment of diet-induced obesity. Importantly, such albumin-based nanoparticles may be a general biocompatible drug carrier system for the controlled release of hydrophobic compounds (e.g., celastrol) for the treatment of obesity and non-alcoholic fatty liver disease.-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats